Rifaximin for Early Graft Dysfunction in Liver Transplants
Effect of Perioperative Oral Rifaximin on Early Graft Dysfunction in Adult Living Donor Liver Transplant
Recruiting
N/A
Interventional Study
Chronic Liver Disease
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 100 (estimated)
- Sponsor
- Institute of Liver and Biliary Sciences, India · Other
Who this trial is looking for
This trial is looking for adult patients who are going to receive a living donor liver transplant. Participants will take an antibiotic called rifaximin during and after their surgery to see if it helps improve liver function after the transplant.
Are You a Good Fit for This Trial?
You may be able to join if
- I am an adult
- I am having a living donor liver transplant
You may not be able to join if
- I did not give my consent
- I am allergic to rifaximin
- I have had a liver transplant before
- I have acute liver failure or acute-on-chronic liver failure
- I am a pediatric patient
- I am currently taking rifaximin
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Liver transplantation has been a lifesaving treatment for individuals with end stage liver disease and acute liver failure. However, initial poor function of a liver allograft after liver transplantation, termed early graft dysfunction (EGD), has been associated with increased allograft loss or mortality after transplantation. EGD in LDLT is multifactorial. Factors affecting EGD are GRWR, ischemia…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* All recipients (adults) undergoing living donor liver transplant in ILBS.
Exclusion Criteria:
* Negative consent
* Hypersensitivity to Rifaximin
* Patients undergoing retransplant
* ALF, ACLF
* Pediatrics patients
* Patients on rifaximin
Contacts